Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis
Brief Summary: The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form
B: Arm Label: AIN457 150 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 150 mg - Start of relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: AIN457 300 mg - Start of Relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Open Label (OL); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Intervention Type: DRUG; Name: AIN457 150 mg; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR) | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg - Fixed Interval (FI), AIN457 300 mg - Open Label (OL), AIN457 300 mg - Start of Relapse (SoR) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR), AIN457 300 mg - Start of Relapse (SoR)
C: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Guselkumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Guselkumab
D: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment

Answer: A